Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Bio-Rad Laboratories, Inc.: Strengths and Weaknesses

Highlights: Bio-Rad Laboratories, Inc.
  • The company is in a robust financial situation considering its net cash and margin position.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses: Bio-Rad Laboratories, Inc.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company benefits from high valuations in earnings multiples.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The company's earnings releases usually do not meet expectations.

Rating Financials

Bio-Rad Laboratories, Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

-
More ratings

Rating Valuation

Bio-Rad Laboratories, Inc. SectorUnited States

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

-

Equity Valuation

P/E

PBR

Dividend Yield

-

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Bio-Rad Laboratories, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Bio-Rad Laboratories, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Bio-Rad Laboratories, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
7.95B
BBB
161B
BBB
101B
BBB
56.12B
AA
53.35B
AAA
42.13B
A
35.29B -
26.57B
BBB
25.79B
AA
20.69B
AAA
-
Average 52.98B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. BIO Stock
  4. Ratings Bio-Rad Laboratories, Inc.